Mechanosensitive Ion Channel PIEZO1 as a Key Regulator of Intestinal Fibrosis in Crohn’s Disease
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Luyao Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Crohn Disease, Ion Channels, Intestinal Mucosa. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Research Program for Colleges and Universities in Anhui Province.
Abstract (Originalsprache)
Background
We aimed to elucidate the function of the mechanosensitive ion channel PIEZO1 in intestinal fibrosis, which is invariably associated with Crohn’s disease (CD) and often results in strictures and obstructions, requiring surgical intervention. Notably, PIEZO1 is strongly expressed in fibrotic tissues and linked with fibrotic progression.
Methods
Intestinal tissues were procured from 28 patients diagnosed with CD and 8 healthy control subjects. Histological and immunofluorescence assays verified that PIEZO1 is substantially overexpressed in fibrotic intestinal tissues and is involved in epithelial‒mesenchymal transition (EMT). Further gene knockout experiments and transcriptome sequencing elucidated the specific role of PIEZO1 in the pathogenesis of intestinal fibrosis in CD. We generated mice with Piezo1 deletion specifically in intestinal epithelial cells (Piezo1f/fVilcre) to validate in vivo that inhibiting Piezo1 function attenuates or reverses intestinal fibrosis associated with CD.
Results
PIEZO1 expression was strongly increased in the fibrotic small intestine of CD patients, thereby promoting EMT and exacerbating intestinal fibrosis. In vivo investigations revealed that the conditional suppression of Piezo1 in intestinal epithelial cells significantly mitigated intestinal fibrosis in dextran sulphate sodium (DSS)- and 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced chronic colitis model mice. In vitro examinations revealed that Piezo1 expression in intestinal epithelial cells preserved the stability of HIF-1α, induced EMT to stimulate the expression of fibrosis-associated molecules, and promoted fibrosis.
Conclusion
PIEZO1 plays a pivotal role in the regulation of intestinal fibrosis by maintaining the levels of HIF-1α, thereby promoting EMT. Therapeutic strategies targeting PIEZO1 could be used to prevent intestinal fibrosis in CD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
- College of Basic Medical Sciences, Anhui Medical University, Hefei, China.
ORCID-Profile: Luyao Zhang, Qiao Mei
Förderung
- National Natural Science Foundation of China
- Natural Science Research Program for Colleges and Universities in Anhui Province
Zitieren
APA
Zhang, L., Liu, Q., Yang, X., Su, C., Ding, H., Hu, J., Han, W., Wu, J., Zhang, M., Zuo, L., & Mei, Q. (2025). Mechanosensitive Ion Channel PIEZO1 as a Key Regulator of Intestinal Fibrosis in Crohn’s Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf041
Vancouver
Zhang L, Liu Q, Yang X, Su C, Ding H, Hu J, et al. Mechanosensitive Ion Channel PIEZO1 as a Key Regulator of Intestinal Fibrosis in Crohn’s Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf041
BibTeX
@article{Zhang2025,
author = {Zhang, Luyao and Liu, Qiuyuan and Yang, Xiaodong and Su, Chang and Ding, Hao and Hu, Jing and Han, Wei and Wu, Juan and Zhang, Manli and Zuo, Li and Mei, Qiao},
title = {Mechanosensitive Ion Channel PIEZO1 as a Key Regulator of Intestinal Fibrosis in Crohn’s Disease},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf041}
}
EUVIMED